GlassScriptPhysician profile
Brian P Cline
NPI 1801819958
$7,675.18
in general payments reported to CMS, 2019-2025
49 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $539 · 2021: $179 · 2022: $1,199 · 2023: $1,195 · 2024: $1,514 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,914.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $906.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $752.52 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $750.44 | 2019-2025 | |
| Exact Sciences Corporation | $684.55 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $629.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $465.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.19 | 2019-2025 | Jardiance |
| Abbvie INC. | $350.79 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Dexcom, INC. | $319.54 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $259.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $245.75 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.67 | 2019-2025 | Xifaxan, Trulance |
| Inari Medical, INC. | $171.42 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amarin Pharma, INC. | $171.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $135.82 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.